RecruitingPhase 2NCT04619862

Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)

Efficacy of Gabapentin in Treating Pain in Children With Severe Neurological Impairment

Sponsor

University of British Columbia

Enrollment

5 participants

Start Date

May 15, 2021

Study Type

INTERVENTIONAL

Conditions

Pain Neuropathic Pain Irritability

Summary

Children born with severe brain-based developmental disabilities frequently experience persistent unexplained periods of pain and irritability, often compounded by a limited capacity to communicate their distress. The investigators call this entity Pain and Irritability of Unknown Origin (PIUO). The rationale of this trial is to identify the clinical effect size of gabapentin in reducing and resolving pain in children with developmental brain disorders, specifically those with severe neurological impairment (SNI).

Eligibility

Min Age: 6 MonthsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Gabapentin and a drug called Placebo for people with irritability, neuropathic pain, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Months to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.